Equity grant gives Organogenesis (ORGO) director 48,828 RSUs vesting 2027

Rhea-AI Filing Summary

Organogenesis Holdings Inc. director Michael Joseph Driscoll received an equity grant in the form of restricted stock units (RSUs) covering 48,828 shares of Class A common stock. The award was granted at no cash cost per share and represents a compensation-related acquisition, not an open-market purchase.

Each RSU converts into one share of Class A common stock upon vesting. The RSUs vest in full on February 15, 2027, meaning Driscoll will receive the underlying shares only if the vesting conditions are satisfied. Following this grant, his directly held Class A share balance reported in this filing is 215,707 shares.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Driscoll Michael Joseph

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Class A Common Stock	48,828	$0.00	--

Holdings After Transaction: Class A Common Stock — 215,707 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Driscoll Michael Joseph

(Last) (First) (Middle)

C/O ORGANOGENESIS HOLDINGS INC.

85 DAN ROAD

(Street)

CANTON MA 02021

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Organogenesis Holdings Inc. [ ORGO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/18/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	02/18/2026		A(1)		48,828	A	$0	215,707	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in full on February 15, 2027.

	/s/ William R. Kolb, Attorney-in-Fact	02/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Organogenesis (ORGO) director Michael Driscoll report on this Form 4?

Michael Driscoll reported receiving a grant of 48,828 restricted stock units of Organogenesis Class A common stock. The grant is compensation under the company’s 2018 Equity Incentive Plan rather than an open-market stock purchase or sale.

How many Organogenesis (ORGO) RSUs were granted to Michael Driscoll?

Michael Driscoll was granted 48,828 restricted stock units of Organogenesis Class A common stock. Each unit represents the contingent right to receive one share when it vests, providing equity-based compensation instead of immediate cash.

When do Michael Driscoll’s Organogenesis (ORGO) RSUs vest?

The restricted stock units granted to Michael Driscoll vest in full on February 15, 2027. At that time, each vested unit converts into one share of Organogenesis Class A common stock, assuming he satisfies any applicable vesting conditions.

What is Michael Driscoll’s Organogenesis (ORGO) share ownership after the RSU grant?

After the reported grant, Michael Driscoll’s directly held Organogenesis Class A share balance is 215,707 shares. This figure reflects his ownership position as reported in the Form 4 immediately following the equity award transaction.

Did Michael Driscoll buy or sell Organogenesis (ORGO) shares on the market?

He did not report any open-market buys or sells. The Form 4 shows a grant or award acquisition of restricted stock units at a stated price of $0.0000 per share, reflecting equity compensation instead of a cash-funded stock trade.

What plan governs Michael Driscoll’s Organogenesis (ORGO) RSU award?

The award was granted under the Organogenesis Holdings Inc. 2018 Equity Incentive Plan. This plan provides stock-based compensation such as restricted stock units, aligning director compensation with long-term shareholder interests through equity rather than only cash.